Exiqon publishes new data for prostate cancer test
Exiqon can now present their prostate cancer test, which can divide patients into different categories depending on how aggressive their disease may be, and with this, the company hopes to enter a USD 750 million market next year.
BY LOUISE WENDT JENSEN
For many years Exiqon and Denmark’s Aarhus University Hospital have collaborated to identify and validate new biomarkers which can be used to diagnose prostate cancer.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Shareholder rebellion brewing at Exiqon
For abonnenter
Exiqon closes in on two new launches
For abonnenter
Exiqon’s US business has kicked into gear
For abonnenter
